A 15 mg/kg dose of rabbit anti-T-lymphocyte globulin (ATLG) was associated with similar graft-vs-host-disease (GVHD), less nonrelapse mortality, and less disease recurrence compared with a 30 mg/kg dose for children with hematological malignancies.
In the multivariable analysis of EFS, 30 mg/kg dose, HLA disparity of more than 1 allele, and high-risk disease were all associated with poorer outcome. Only the high-risk disease group was significantly associated with an increased risk for relapse, whereas the 30-mg/kg dose was associated with an increased risk for nonrelapse mortality.
Locatelli F, Bernardo ME, Bertaina A, et al. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(8):1126-1136. doi: 10.1016/S1470-2045(17)30417-5.
... to read the full story